ArticleBreast cancer (Dove Medical Press)2025
Integrated Pan-Cancer Profiling and Breast Cancer Validation Identify BEND3 as a Potential Prognostic and Immune Biomarker.
Article in Breast cancer (Dove Medical Press), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Intratumoral PD-1Medical oncology (Northwood, London, England) · 2026Article
- High expression of CD74 is associated with poor prognosis and tumor immune infiltration in Acute Myeloid Leukemia.Discover oncology · 2026Article
- Construction of a risk model based on folate metabolism-related genes to predict prognosis and immunological characteristics of stomach adenocarcinoma.Discover oncology · 2026Article
- Article
- Glycosylation-related gene risk model and functional validation of OSTC and TUBA1C in lung adenocarcinoma.Respiratory research · 2026Article
- The Ki-67 proliferation index in tertiary lymphoid structures as a predictor of survival outcomes in patients with resectable non-small cell lung cancer.BMC cancer · 2026Article
- Whole blood miRNA expression signatures as predictors of neoadjuvant chemotherapy response in triple-negative breast cancer.Hereditas · 2026Article
- CLTC expression in oral squamous cell carcinoma: insights into prognostic value and immune microenvironment modulation.World journal of surgical oncology · 2026Article
- Ferroptosis-related gene EPAS1 suppresses breast cancer progression by inhibiting M2 macrophage polarization.Discover oncology · 2026Article
- Identification of serum 5'tRF-Val as a promising non-invasive biomarker for early detection of esophageal cancer.Scientific reports · 2026Article
- The role of alternative splicing in gastric cancer.Biology direct · 2026Review
- Improving response evaluation and treatment adaptation in hormone receptor-positive/human epidermal growth factor receptor 2-positive breast cancer.Breast cancer (Tokyo, Japan) · 2026Article
- Integrated multi-omics analysis and functional experiments reveals PPAP2C as a potential prognostic biomarker and therapeutic target in breast cancer.Frontiers in pharmacology · 2026Article
- Development and internal validation of a radiomics-clinical combined model for predicting axillary pathological complete response in clinically node-positive breast cancer patients after neoadjuvant chemotherapy.Frontiers in oncology · 2026Article
- Multi-Omics Characterization of ABHD12 Across Pan-Cancer and Validation of Its Role in Promoting Proliferation and Metastasis in Breast Cancer.Breast cancer (Dove Medical Press) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: BEND3 is implicated in various physiological processes, including chromatin regulation, cell cycle regulation, etc.; nonetheless, its function in cancer is not well comprehended. Methods: Using public databases including UCSC Xena, TCGA, GTEx, and GEO, we conducted a comprehensive pan-cancer analysis to evaluate the clinical relevance of BEND3 across 33 cancer types. We analyzed genetic alterations, copy number variations (CNVs), and methylation profiles of BEND3, and explored its associations with tumor mutational burden (TMB), microsatellite instability (MSI), immune checkpoint molecules, and the tumor immune microenvironment. A protein-protein interaction (PPI) network and functional enrichment analysis were performed to investigate potential molecular mechanisms. In vitro, BEND3 expression was assessed by immunohistochemistry (IHC), Western blot (WB), and qRT-PCR. Cell Counting Kit-8 (CCK-8), colony formation, and wound healing assays were performed to validate BEND3's oncogenic role in breast cancer cell lines. Results: Our results show that BEND3 is frequently overexpressed in multiple cancers, including breast, liver, lung, thyroid, and gastric cancers, among others, and is associated with poor prognosis. Its expression correlates with TMB, MSI, immune checkpoint molecules, and immunoinfiltration, suggesting a role in tumor immunity. Functional analysis indicates involvement in key cancer-related pathways. In breast cancer, BEND3 was upregulated in clinical tissues and cell lines, and in vitro experiments demonstrated that BEND3 overexpression promoted the proliferation, migration, and invasion of breast cancer cells, whereas its knockdown suppressed these phenotypes. Conclusion: Our findings suggest BEND3 is a potential prognostic and immune-related cancer biomarker. Its overexpression in multiple cancers, association with poor survival, and role in tumor immunity support its oncogenic function. Functional analysis indicates it may regulate key cancer pathways. Importantly, in vitro experiments confirm its tumor-promoting effects in breast cancer, providing a foundation for further study of BEND3's mechanisms and therapeutic implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.